EU Approval Decision Imminent For First CD20xCD3 Bispecific Antibody

 
• By Neena Brizmohun

If Roche gets the nod from the European Medicines Agency for mosunetuzumab this week, it could become the first company to market a CD20xCD3 bispecific antibody for follicular lymphoma.

Question marks background. High resolution 3d render
The EU marketing application for mosunetuzumab is up for an opinion • Source: Alamy

More from Europe

More from Geography